PREZISTA 400 MG Israel - English - Ministry of Health

prezista 400 mg

j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 400 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.

PREZISTA 600 MG Israel - English - Ministry of Health

prezista 600 mg

j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 600 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.

PREZISTA 75 MG Israel - English - Ministry of Health

prezista 75 mg

j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 75 mg - darunavir - darunavir - adult patients:prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv-1 rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment-experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients .pediatric patients:prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv-1 infection in treatment-experienced pediatric patients 6 years of age and older .this indication is based on 24 week analyses of plasma hiv-1 rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment-experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with prezista/rtv: - treatment history and, when available, genotypic or phenotypic testing, should guide the use of prezista/rtv. - the use of other active agents with prezista/rtv is associated with a greater likelihood of treatment response.

PREZISTA 150 MG Israel - English - Ministry of Health

prezista 150 mg

j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 150 mg - darunavir - darunavir - adult patients:prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv-1 rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment-experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients .pediatric patients:prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv-1 infection in treatment-experienced pediatric patients 6 years of age and older .this indication is based on 24 week analyses of plasma hiv-1 rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment-experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with prezista/rtv: - treatment history and, when available, genotypic or phenotypic testing, should guide the use of prezista/rtv. - the use of other active agents with prezista/rtv is associated with a greater likelihood of treatment response.

CARVEDEXXON 6.25 Israel - English - Ministry of Health

carvedexxon 6.25

dexcel ltd, israel - carvedilol - tablets - carvedilol 6.25 mg - carvedilol - carvedilol - treatment of symptomatic congestive heart failure. carvedexxon may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ace inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.

CARVEDEXXON 12.5 Israel - English - Ministry of Health

carvedexxon 12.5

dexcel ltd, israel - carvedilol - tablets - carvedilol 12.5 mg - carvedilol - carvedilol - treatment of symptomatic congestive heart failure. carvedexxon may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ace inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.

EXFORGE 5 MG80 MG Israel - English - Ministry of Health

exforge 5 mg80 mg

novartis israel ltd - amlodipine as besylate; valsartan - film coated tablets - amlodipine as besylate 5 mg; valsartan 80 mg - amlodipine - amlodipine - treatment of essential hypertension. exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.

EXFORGE 5 MG160 MG Israel - English - Ministry of Health

exforge 5 mg160 mg

novartis israel ltd - amlodipine as besylate; valsartan - film coated tablets - amlodipine as besylate 5 mg; valsartan 160 mg - amlodipine - amlodipine - treatment of essential hypertension. exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.

EXFORGE 10 MG160 MG Israel - English - Ministry of Health

exforge 10 mg160 mg

novartis israel ltd - amlodipine as besylate; valsartan - film coated tablets - amlodipine as besylate 10 mg; valsartan 160 mg - amlodipine - amlodipine - treatment of essential hypertension. exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.

CRESTOR  10 MG Israel - English - Ministry of Health

crestor 10 mg

astrazeneca (israel) ltd - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 10 mg - rosuvastatin - rosuvastatin - treatment of adults with:• primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate.• homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate